Fjarde Ap Fonden Vertex Pharmaceuticals Inc Transaction History

Fjarde Ap Fonden

$9.8 Billion
Q3 2024

A detailed history of Fjarde Ap Fonden transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fjarde Ap Fonden holds 71,988 shares of VRTX stock, worth $29.4 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

71,988

Previous 70,988 1.41%

Holding current value

$29.4 Million

Previous $29.7 Million 12.83%

% of portfolio

0.34%

Previous 0.33%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$460.0 - $505.78 $460,000 - $505,780	1,000 Added 1.41%	71,988 $33.5 Million
Q1 2024 Apr 25, 2024	BUY	$407.69 - $446.08 $815,380 - $892,160	2,000 Added 2.9%	70,988 $29.7 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $857,500 - $1.03 Million	-2,500 Reduced 3.5%	68,988 $28.1 Million
Q3 2023 Oct 23, 2023	SELL	$338.18 - $362.46 $405,816 - $434,952	-1,200 Reduced 1.65%	71,488 $24.9 Million
Q2 2023 Aug 02, 2023	BUY	$314.42 - $351.91 $2.11 Million - $2.36 Million	6,700 Added 10.15%	72,688 $25.6 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $254,907 - $290,790	-900 Reduced 1.35%	65,988 $20.8 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $9.97 Million - $11.2 Million	-34,898 Reduced 34.29%	66,888 $19.3 Million
Q2 2022 Aug 11, 2022	BUY	$234.96 - $292.55 $7.45 Million - $9.27 Million	31,700 Added 45.23%	101,786 $28.7 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $88,789 - $104,648	-401 Reduced 0.57%	70,086 $18.3 Million
Q4 2021 Feb 15, 2022	SELL	$177.01 - $223.45 $123,907 - $156,415	-700 Reduced 0.98%	70,487 $15.5 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $99,401 - $111,238	-548 Reduced 0.76%	71,187 $12.9 Million
Q2 2021 Aug 12, 2021	SELL	$187.49 - $221.1 $1.05 Million - $1.24 Million	-5,600 Reduced 7.24%	71,735 $14.5 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $62,106 - $72,393	300 Added 0.39%	77,335 $16.6 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $476,123 - $635,007	-2,300 Reduced 2.9%	77,035 $18.2 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $1.35 Million - $1.61 Million	5,300 Added 7.16%	79,335 $21.6 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $979,034 - $1.28 Million	4,342 Added 6.23%	74,035 $21.5 Million
Q1 2020 May 11, 2020	SELL	$199.77 - $247.81 $59,931 - $74,343	-300 Reduced 0.43%	69,693 $16.6 Million
Q4 2019 Feb 10, 2020	BUY	$166.71 - $223.91 $733,524 - $985,204	4,400 Added 6.71%	69,993 $15.3 Million
Q3 2019 Oct 31, 2019	BUY	$166.23 - $187.09 $232,722 - $261,926	1,400 Added 2.18%	65,593 $11.1 Million
Q2 2019 Jul 17, 2019	SELL	$164.61 - $190.37 $1.23 Million - $1.43 Million	-7,500 Reduced 10.46%	64,193 $11.8 Million
Q1 2019 Apr 29, 2019	BUY	$163.73 - $194.7 $1.97 Million - $2.34 Million	12,033 Added 20.17%	71,693 $13.2 Million
Q4 2018 Jan 31, 2019	SELL	$151.91 - $192.21 $1.17 Million - $1.48 Million	-7,700 Reduced 11.43%	59,660 $9.89 Million
Q3 2018 Nov 09, 2018	SELL	$167.73 - $192.74 $486,752 - $559,331	-2,902 Reduced 4.13%	67,360 $13 Million
Q2 2018 Jul 12, 2018	BUY	$145.72 - $169.96 $37,012 - $43,169	254 Added 0.36%	70,262 $11.9 Million
Q1 2018 May 07, 2018	BUY	$151.6 - $177.13 $112,790 - $131,784	744 Added 1.07%	70,008 $11.4 Million
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $1.5 Million - $1.69 Million	10,892 Added 18.66%	69,264 $10.4 Million
Q3 2017 Nov 07, 2017	BUY	$148.13 - $162.24 $166,201 - $182,033	1,122 Added 1.96%	58,372 $8.88 Million
Q2 2017 Aug 08, 2017	BUY	N/A	57,250	57,250 $7.38 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account